Reshma Kewalramani, M.D., FASN
Chief Executive Officer and President

Reshma Kewalramani, M.D., FASN, is the Chief Executive Officer and President at Vertex Pharmaceuticals. Dr. Kewalramani has dedicated her career to improving the lives of patients, including the last 15+ years through the development of new medicines. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. During that time, Vertex made remarkable progress to bring new medicines to more people with cystic fibrosis (CF) around the world, including the approval of SYMDEKO®/SYMKEVI® and the rapid approval of TRIKAFTA®/KAFTRO® to potentially treat up to 90% of all people with CF. Under Dr. Kewalramani’s leadership as CEO, Vertex has expanded its leadership in CF and advanced several programs into the clinic, including APOL1-mediated kidney disease, sickle cell disease, beta thalassemia and type 1 diabetes.

Dr. Kewalramani is passionate about developing and supporting the next generation of scientists and giving back to her community. She is a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM. She is also a member of the Boston University School of Medicine Dean’s Advisory Board, the Massachusetts General Hospital Board of Trustees, and the Ginkgo Bioworks board of directors. She is a Fellow of the American Society of Nephrology and was on the inaugural board of directors of the Kidney Health Initiative.

She is the recipient of the Harvard Medical School Excellence in Teaching Award. In 2019, Dr. Kewalramani received the TiE Boston Healthcare Leadership Award and was named one of Boston Business Journal’s 10 People Transforming Healthcare. In 2020, Business Insider named her one of 10 people transforming health care, and she was included on the PharmaVOICE 100 list of the most inspiring and influential leaders in the life sciences and Boston Business Journal’s list of Women Who Mean Business. In 2021, Dr. Kewalramani received the Golden Door Award from the International Institute of New England and was named a New Englander of the Year by the New England Council.

Vertex and the Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated.
Under her leadership as CEO, Vertex was ranked #2 on The Commonwealth Institute’s Top Women-Led Businesses in Massachusetts in 2021.

Dr. Kewalramani completed her internship and residency in internal medicine at the Massachusetts General Hospital and her fellowship in nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. She received her medical degree, with honors, from the seven-year medicine program at the Boston University School of Medicine and completed the General Management Program at Harvard Business School.